Marshall Wace LLP Buys 253,421 Shares of Vera Therapeutics, Inc. (NASDAQ:VERA)

Marshall Wace LLP lifted its holdings in shares of Vera Therapeutics, Inc. (NASDAQ:VERA - Free Report) by 43.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 837,146 shares of the company's stock after acquiring an additional 253,421 shares during the quarter. Marshall Wace LLP owned 1.32% of Vera Therapeutics worth $35,403,000 as of its most recent filing with the SEC.

Several other institutional investors have also modified their holdings of VERA. SG Americas Securities LLC increased its position in Vera Therapeutics by 116.7% in the fourth quarter. SG Americas Securities LLC now owns 20,270 shares of the company's stock worth $857,000 after buying an additional 10,916 shares during the period. Lord Abbett & CO. LLC increased its stake in shares of Vera Therapeutics by 41.1% in the third quarter. Lord Abbett & CO. LLC now owns 426,014 shares of the company's stock valued at $18,830,000 after purchasing an additional 124,197 shares during the period. Barclays PLC raised its holdings in shares of Vera Therapeutics by 94.1% during the third quarter. Barclays PLC now owns 85,395 shares of the company's stock valued at $3,774,000 after buying an additional 41,394 shares during the last quarter. Geode Capital Management LLC boosted its position in shares of Vera Therapeutics by 2.1% during the third quarter. Geode Capital Management LLC now owns 1,004,665 shares of the company's stock worth $44,415,000 after buying an additional 20,223 shares during the period. Finally, Raymond James Financial Inc. bought a new position in Vera Therapeutics in the 4th quarter worth approximately $2,948,000. Institutional investors and hedge funds own 99.21% of the company's stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on VERA. Wolfe Research assumed coverage on shares of Vera Therapeutics in a report on Tuesday, February 4th. They issued an "outperform" rating and a $49.00 price objective for the company. Guggenheim lifted their price target on shares of Vera Therapeutics from $59.00 to $61.00 and gave the stock a "buy" rating in a research report on Thursday, February 27th. JPMorgan Chase & Co. reduced their price objective on shares of Vera Therapeutics from $77.00 to $71.00 and set an "overweight" rating for the company in a research note on Tuesday, March 4th. Finally, The Goldman Sachs Group assumed coverage on Vera Therapeutics in a research report on Tuesday, January 28th. They issued a "buy" rating and a $58.00 target price for the company. One investment analyst has rated the stock with a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Vera Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $64.67.

Vera Therapeutics Stock Performance

Shares of NASDAQ VERA traded up $0.23 during trading hours on Thursday, hitting $22.57. 249,479 shares of the company's stock were exchanged, compared to its average volume of 907,263. The stock has a market capitalization of $1.44 billion, a price-to-earnings ratio of -8.65 and a beta of 1.28. The company's 50-day moving average price is $25.46 and its 200-day moving average price is $36.13. The company has a debt-to-equity ratio of 0.17, a current ratio of 13.76 and a quick ratio of 13.76. Vera Therapeutics, Inc. has a 1-year low of $18.53 and a 1-year high of $51.61.

Vera Therapeutics (NASDAQ:VERA - Get Free Report) last released its earnings results on Wednesday, February 26th. The company reported ($0.72) earnings per share for the quarter, topping analysts' consensus estimates of ($0.83) by $0.11. On average, sell-side analysts expect that Vera Therapeutics, Inc. will post -2.89 earnings per share for the current fiscal year.

Vera Therapeutics Profile

Vera Therapeutics, Inc, a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial.